Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
IL-17 Modulators Market: Competitive Landscape, Pipeline, and Market Analysis 2023
IL-17 Modulators Market: Competitive Landscape, Pipeline, and Market Analysis 2023
IL-17 (Interleukin-17) is a family of proinflammatory cytokines that mediate normal inflammatory and immune responses, also it has the most prominent role in host defense and autoimmunity. IL-17 binds to IL-17 receptors which are expressed in various cell types. The IL-17 signaling pathway promotes angiogenesis and the release of proinflammatory cytokines, chemokines, and mediators of tissue damage. IL-17 inhibitors act by preventing the interaction of IL-17 with the IL-17 receptor and also the activation of the IL-17 receptor signaling pathway associated with inflammatory processes. IL-17 inhibitors are marketed for conditions including ankylosing spondylitis, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, pustular psoriasis, and others. Novartis, Eli Lilly & Company, Bausch Health, Biocad, AbbVie, Roche, Merck (MSD), J&J, and LEO Pharma are some of the major players in the IL-17 inhibitors market.
Key Market Developments:
Approved Drug Molecules and Brand Names for IL-17 Modulators:
Drugs under the Pipeline for IL-17 Modulators:
Clinical Activity and Developments of IL-17 Modulators:
At present, there are about 39 drug products in IL-17 inhibitors, among which 12 of them are in the market for treatments of various disease conditions, and the rest are in clinical development phases.
|
Molecule Name |
Number of Studies |
|
Vidofludimus (IMU-838) |
12 |
|
Vunakizumab (SHR-1314) |
12 |
|
Izokibep (ABY-035) |
9 |
|
CJM112 |
6 |
|
Remtolumab (ABT-122) |
5 |
|
JS005 |
4 |
|
MOR106 |
4 |
|
Gumokimab (AK111) |
4 |
|
Isomyosamine (MYMD-1) |
4 |
|
Sonelokimab (M1095) |
4 |
|
Tibulizumab (ZB-106) |
4 |
|
608 |
3 |
|
CNTO6785 |
3 |
|
HB0017 |
3 |
|
KIO-101 |
3 |
|
Afasevikumab (NI 1401) |
3 |
|
BAT2306 (Secukinumab biosimilar) |
2 |
|
Jinlixi (Xeligekimab) |
2 |
|
LY3509754 |
2 |
|
SCH900117 |
2 |
|
Izumerogant (IMU-935) |
2 |
|
Perakizumab (RG4934) |
2 |
|
BITS7201A |
2 |
|
DC-806 |
1 |
|
JNJ-61178104 |
1 |
|
LP0200 |
1 |
|
NBL-012 |
1 |
|
SCT650C |
1 |
|
SFA-002 |
1 |
|
SM17 |
1 |
|
XKH001 |
1 |
|
ZL-1102 |
1 |
|
anti-TNF/IL-17A FynomAB (COVA322) |
1 |
IL-3 inhibitors such as Secukinumab, Basiliximab, Ustekinumab, Dupilumab, Ixekizumab, and others are used in the treatment of ankylosing spondylitis, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, pustular psoriasis, and others. Some of them have also been registered for hidradenitis suppurativa and juvenile rheumatoid arthritis, are in phase III for giant cell arteritis, graves ophthalmology, lupus nephritis, polymyalgia rheumatica, and rotator cuff injuries, in phase II for atopic dermatitis, necrobiosis lipoidica, pyoderma gangrenosum, varicose ulcer, and others.
The autoimmune diseases affect as much as 4.5 percent of the world’s population. Psoriasis and rheumatoid arthritis are the most commonly occurring autoimmune diseases. According to the Autoimmune Registry Inc (ARI) report 2020, about 15 to 30 million people in the USA suffer from autoimmune disease, which primarily affects women aged 20 to 40. The growing burden of autoimmune diseases indicates the market growth potential for IL-3 inhibitors. Eli Lilly & Company’s Taltz had a total sale of US$ 2,482 million in 2022, where the sale alone in the USA was US$ 1,724 million. Novartis’s Cosentyx (US$ 4.8 billion) sales grew in emerging growth markets, Europe, China, and Japan, and all of its patents will expire in 2031.
Latin America
Europe
Asia Pacific
Middle East
North America
Download Free Sample Report
Siliq (Brodalumab), Arcalyst (Rilonacept), Cosentyx (Secukinumab), Simulect (Basiliximab), Stelara (Ustekinumab), Dupixent (Dupilumab) are the few approved IL-17 Modulators.
Novartis, Eli Lilly & Company, Bausch Health, Biocad, AbbVie, Roche, Merck (MSD), J&J, and LEO Pharma are some of the major players in the IL-17 inhibitors market.
Major indications for IL-17 modulators are ankylosing spondylitis, non-radiographic axial spondylarthritis, plaque psoriasis, psoriatic arthritis, and pustular psoriasis.
There are a total of 31 molecules in clinical development phases for IL-17 modulators.
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.